Leukocyte Adhesion Deficiency Management Market: By Treatment (Hematopoietic Stem Cell Transplantation, Recombinant Human Interferon-gamma Treatment, Prophylactic Immunoglobulin Therapy, Antimicrobial Therapy, Prophylactic Therapy, Fucose Supplementation, Monoclonal Antibodies, Coagulation Factors), By End Users (Hospitals, Specialty Clinics, Others), and Geography

Leukocyte Adhesion Deficiency Management Market size was valued at USD 6,223.8 million in 2023 and is poised to grow at an 6.8% CAGR from 2024 to 2030. Leukocyte Adhesion Deficiency (LAD) is a rare autosomal recessive disorder characterized by immunodeficiency resulting in recurrent infections. The advent of genome sequencing and increased interest in genome studies have played an important role in enhancing and understanding the overall genetics of leukocyte adhesion deficiency. Contemporary research has generated new frontiers for understanding the pathogenesis of common variable primary immunodeficiency. Recently, the adoption of DNA sequencing, RNA sequencing, epigenetic, and proteomic profiles is growing, to assess common variable primary immunodeficiency including leukocytic adhesion deficiency. Scientists and researchers are increasingly focusing on understanding the genetics of primary immunodeficiency which will help in expanding the market. Moreover, the increasing prevalence of spinal cord injuries and primary immunodeficiency is rising, furthering the demand for novel treatments.

Credited to several discoveries in monogenic forms of common variable primary immunodeficiency, significant progress in sequencing technologies is triggered. In the past decade, owing to advancements in technology and research, participants of the primary immunodeficiency market are swaying toward the use of omics-based technologies and integrating next-generation platforms in the leukocyte adhesion deficiency therapeutics which will also help in market expansion in the forecast period. Moreover, as the leukocyte adhesion deficiency management market continues to evolve, it provides various opportunities for stakeholders to collaborate, innovate, and invest in research and development initiatives to further advance treatment modalities and address unmet medical needs in the field of leukocyte adhesion deficiency management. However, the growth of the leukocyte adhesion deficiency therapeutics market is expected to be restrained due to the high cost of immunotherapy and the side effects of immunodeficiency disease treatments like leukocyte adhesion deficiency treatment. Moreover, stem cell transplantation therapies have a very high success rate. In addition, stem cell reconstitution is a first-line treatment for severe leukocyte adhesion deficiency type I. These benefits provided by this therapy will augment this segment’s growth during the forecast period.

Leukocyte Adhesion Deficiency Management Market Key Developments:

• In September 2020, Octapharma USA Inc. received Medicare Part B approval for Cutaquig, a drug used for treating humoral immunodeficiency in adults and children.
• In September 2022, Lactiga Therapeutics raised US$ 1.6 million in oversubscribed pre-seed financing for developing therapeutics for patients with primary immunodeficiency diseases.
• In April 2022, Pharming Group N.V. presented data from its Phase II and Phase III clinical trial of leniolisib, developed for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a primary immunodeficiency.